OMCL — Omnicell, Inc. stock price, charts and financials

NASDAQ·Healthcare·Medical - Equipment & Services·USA

Latest market price

37.15

-0.50-1.33%

Overview Short InterestFilings

OMCLQT31Omnicell, Inc.·NASDAQ

Overview Short InterestFilings

37.15-1.33%

News

Down 1.3% — Here's Why Omnicell (OMCL) is a Strong Value Stock (zacks.com).

Medium confidence

Loading chart...

Signal & projected range

Earnings big beat — drift (PEAD)Historical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

DRTS+9.73%$13.08 MLAB-3.15%$101.14 HIMS+4.35%$32.16 LAB-5.28%$0.82 PTGX+2.67%$135.81 HQY+0.58%$104.97 CRNX+0.12%$83.86 BIO-0.55%$332.88

Snapshot

Index	-	P/E	44.23	EPS (ttm)	0.84	Insider Own	3.97%	Shs Outstand	45.48M	Perf Week	-13.70%

Market Cap	1.69B	Forward P/E	17.18	EPS next Y	2.16	Insider Trans	-1.65%	Shs Float	43.91M	Perf Month	-17.88%

Enterprise Value	1.59B	PEG	10.36	EPS next Q	0.47	Inst Own	-	Short Float	8.17%	Perf Quarter	-14.48%

Income	38.00M	P/S	1.35	EPS this Y	169.35%	Inst Trans	-	Short Ratio	5.46	Perf Half Y	-23.72%

Sales	1.25B	P/B	1.31	EPS next Y	-4.42%	ROA	1.96%	Short Interest	3.59M	Perf YTD	-17.99%

Book/sh	28.41	P/C	5.79	EPS next 5Y	4.27%	ROE	3.13%	52W High	55.00 -32.45%	Perf Year	24.83%

Cash/sh	6.42	P/FCF	11.38	EPS past 3/5Y	-28.26% -43.06%	ROIC	2.43%	52W Low	29.06 27.84%	Perf 3Y	-40.99%

Dividend Est.	-	EV/EBITDA	15.11	Sales past 3/5Y	-2.94% 5.85%	Gross Margin	44.77%	Volatility	6.86% 4.71%	Perf 5Y	-75.45%

Dividend TTM	-	EV/Sales	1.27	EPS Y/Y TTM	211.11%	Oper. Margin	4.73%	ATR (14)	2.29	Perf 10Y	4.41%

Dividend Ex-Date	-	Quick Ratio	1.43	Sales Y/Y TTM	12.14%	Profit Margin	3.13%	RSI (14)	38.34	Recom	2.53

Dividend Gr. 3/5Y	-	Current Ratio	1.64	EPS Q/Q	108.89%	SMA20	-12.58%	Beta	0.97	Target Price	55.80

Payout	0.00%	Debt/Eq	0.16	Sales Q/Q	7.22%	SMA50	-11.17%	Rel Volume	1.70	Prev Close	37.65

Employees	3,525	LT Debt/Eq	0.16	Earnings	Oct 29	SMA200	-8.11%	Avg Volume	704.79K	Price	37.15

IPO Date	Aug 07, 2001	Option/Short	Yes / Yes	EPS/Sales Surpr.	101.07% 0.64%	Net Debt/EBITDA	-0.98	Volume	1,200,542	Change	-1.33%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-31-26	Reiterated	Wells Fargo	Overweight	$52 → $50
Jul-31-26	Reiterated	Keybanc	Overweight	$70 → $65
Apr-29-26	Reiterated	Craig-Hallum	Buy	$53 → $55
Mar-13-26	Reiterated	UBS		$53 → $60
Feb-06-26	Reiterated	Piper Sandler	Overweight	$55 → $49
Jan-16-26	Reiterated	UBS		$53
Jan-08-26	Upgrade	Keybanc	Sector Weight → Overweight	$60
Jan-05-26	Reiterated	Wells Fargo	Overweight	$35 → $52
Aug-11-25	Reiterated	Piper Sandler	Overweight	$61 → $55
May-14-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$40 → $35

Latest News

Aug-04-26

Aug-04-2610:41AM

Here's Why Omnicell (OMCL) is a Strong Value Stockzacks.com

Jul-31-26

Jul-31-2607:59PM

Is Omnicell Inc (OMCL) a Bargain After 4.7% Drop? GF Value Says Undervaluedgurufocus.com

11:04AM

OMCL Q2 Earnings Call Highlights Titan XT Pipeline Growthzacks.com

10:30AM

Wells Fargo Maintains Overweight on Omnicell, Lowers Price Target to $50Benzinga

04:13AM

Dimensional Fund Advisors LP Acquires 137,834 Shares of Omnicell, Inc. $OMCLdefenseworld.net

Jul-30-26

Jul-30-2604:01PM

EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccinationbusinesswire.com

02:05PM

Omnicell Q2 Earnings Call Highlightsmarketbeat.com

12:03PM

Omnicell, Inc. (OMCL) Q2 2026 Earnings Call Transcriptseekingalpha.com

08:51AM

Omnicell (OMCL) Q2 Earnings and Revenues Top Estimateszacks.com

06:30AM

Omnicell Announces Second Quarter 2026 Financial Resultsbusinesswire.com

Jul-23-26

Jul-23-2612:35PM

Nvidia, Teradyne, and Omnicell Earnings Set to Test Robotics Sector’s Divergent MomentumChartMill

Jul-21-26

Jul-21-2612:36PM

Omnicell to Report Q2 Earnings: OmniSphere in Focuszacks.com

Jul-09-26

Jul-09-2603:21PM

Should You Continue to Hold OMCL Stock in Your Portfolio Now?zacks.com

Jul-07-26

Jul-07-2611:01AM

What's Fueling Omnicell Stock's 52.6% Rally Over the Past Year?zacks.com

Jul-06-26

Jul-06-2612:35PM

Beyond the AI Titans: Niche Automation Plays Show Strong Momentum and Earnings AccelerationChartMill

Company

Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	1,247	1,185	1,112	1,147	1,296	1,132	892	897	787
Cost of Goods Sold Incl. D&A	689	677	641	647	707	577	479	460	415
Gross Profit	558	508	471	500	589	555	413	437	372
Selling, General and Administrative Excl. Other	410	409	380	426	486	389	308	290	263
Research and Development	89	88	90	93	105	76	70	69	65
Other Operating Expense	0	-1	1	0	0	0	0	0	0
Operating Income	58	12	0	-19	-2	90	36	78	44
Interest Expense	4	4	5	0	0	22	2	6	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	6	4	30	-1	0	-1	-4	1	-9
Net Income Before Taxes	62	11	26	-20	-2	66	29	74	36
Income Taxes	23	9	13	0	-8	-12	-3	13	-2
Consolidated Net Income	38	2	13	-20	6	78	32	61	38
Net Income From Continuing Operations	38	2	13	-20	6	78	32	61	38
Net Income	38	2	13	-20	6	78	32	61	38
EPS (Recurring)	0.85	0.04	0.27	-0.45	0.13	1.79	0.76	1.48	0.96
EPS (Basic, Before Extraordinaries)	0.85	0.04	0.27	-0.45	0.13	1.79	0.76	1.48	0.96
EPS (Diluted)	0.84	0.04	0.27	-0.45	0.12	1.62	0.74	1.43	0.93
EBITDA	105	102	120	80	97	173	107	142	96
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	44.23	1,022.57	164.89	—	420.17	111.38	162.19	57.15	65.85
Price To Sales Ratio	1.34	1.76	1.84	1.48	1.71	6.85	5.79	3.74	3.03
Gross Margin	44.75	42.87	42.36	43.59	45.45	49.03	46.30	48.72	47.27
Operating Margin	4.65	1.01	0.00	-1.66	-0.15	7.95	4.04	8.70	5.59
Net Margin	3.05	0.17	1.17	-1.74	0.46	6.89	3.59	6.80	4.83
Shares Outstanding	45	46	46	45	44	43	43	41	39
Market Capitalization	1,672	2,084	2,048	1,693	2,218	7,759	5,161	3,351	2,388
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LIPPS RANDALL A	CHAIRMAN, CEO	Jul 15 '26	Sale	47.00	10,000	470,000	345,861	Jul 17
Manley Corey J	EVP&CHIEF LEGAL/ADMIN OFFICER	May 18 '26	Sale	43.22	5,025	217,181	112,783	May 19
Njoku Nnamdi	EVP, Chief Operating Officer	May 18 '26	Sale	43.22	3,090	133,550	154,785	May 19
Manley Corey J	EVP&CHIEF LEGAL/ADMIN OFFICER	Mar 16 '26	Sale	34.69	7,405	256,879	96,717	Mar 17
Manley Corey J	EVP&CHIEF LEGAL/ADMIN OFFICER	Feb 17 '26	Sale	36.59	4,243	155,251	85,496	Feb 18
Manley Corey J	EVP&CHIEF LEGAL/ADMIN OFFICER	Jan 08 '26	Sale	49.90	6,106	304,689	91,674	Jan 12
Manley Corey J	EVP&CHIEF LEGAL/ADMIN OFFICER	Dec 16 '25	Sale	43.30	278	12,037	97,780	Dec 17
Manley Corey J	EVP&CHIEF LEGAL/ADMIN OFFICER	Dec 03 '25	Sale	39.90	6,106	243,629	98,282	Dec 05
LIPPS RANDALL A	CHAIRMAN, PRESIDENT AND CEO	Dec 01 '25	Sale	35.97	28,250	1,016,093	386,648	Dec 03
LIPPS RANDALL A	CHAIRMAN, PRESIDENT AND CEO	Dec 01 '25	Option Exercise	27.70	28,250	782,525	414,898	Dec 03
Manley Corey J	EVP&CHIEF LEGAL/ADMIN OFFICER	Nov 17 '25	Sale	34.90	3,473	121,208	104,388	Nov 18
Manley Corey J	EVP&CHIEF LEGAL/ADMIN OFFICER	Sep 12 '25	Sale	33.25	3,880	129,010	110,653	Sep 16
LIPPS RANDALL A	CHAIRMAN, PRESIDENT AND CEO	Mar 14 '25	Buy	33.13	10,561	349,874	333,610	Mar 18
PARRISH MARK W	Director	Dec 10 '24	Sale	47.30	12,000	567,638	58,427	Dec 12
MELLON CHRISTINE MARIE	EVP, EXECUTIVE ADVISOR	Jun 09 '23	Sale	73.14	7,951	581,568	14,876	Jun 12

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.